%PDF-1.4
%
19 0 obj
<>
endobj
16 0 obj
<>
endobj
68 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-04-09T16:51:54Z
2024-03-28T18:28:10-07:00
QuarkXPressª 4.11: AdobePS 8.6 (219)
2024-03-28T18:28:10-07:00
application/pdf
Heather
2002-692.may
uuid:21a80ea0-1dd2-11b2-0a00-2c0a275d6100
uuid:21a80ea4-1dd2-11b2-0a00-aa0000000000
endstream
endobj
5 0 obj
<>
endobj
6 0 obj
<>
endobj
20 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
74 0 obj
[78 0 R]
endobj
75 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
[(RESUL)91.7 (TS)]TJ
/T1_1 1 Tf
0.30949 Tw 0 -1.2 TD
(Eight cases of HS were diagnosed since 1999. In one)Tj
-0.00909 Tw T*
(patient, ferritin level was unavailable. Causes of HS, ferritin)Tj
0.07069 Tw T*
(levels, percentage of ferritin glycosylation, and the time of)Tj
0.0914 Tw T*
(sampling \(during acute disease or remission\) are shown in)Tj
0.2701 Tw T*
[(T)69.9 (able 1. )17.7 (The underlying diseases were 6 cases of non-)]TJ
0.1319 Tw T*
[(Hodgkin\325)54.8 (s malignant lymphomas \(NHML\) and 2 cases of)]TJ
0.0251 Tw T*
(severe drug hypersensitivity syndrome, an unusual cause of)Tj
-0.0002 Tc 0 Tw T*
(HS)Tj
0 Tc 6.5 0 0 6.5 66.7783 620.4615 Tm
(8)Tj
-0.00011 Tc 0.1376 Tw 10 0 0 10 70.0283 617.1616 Tm
(. Ferritin blood level was high in all cases during the)Tj
0.0966 Tw -1.6028 -1.2 Td
[(acute phase, mean 7545 \261)-331.5 (7386 \265)-76 (g/l \(95% CI 189\) versus)]TJ
0.10921 Tw T*
(usual values in both male and female patients of 3 to 244)Tj
0.15581 Tw T*
[(\265)-76 (g/l. Interestingly)64.8 (, as in )54.8 (ASD, the percentage of glycosy-)]TJ
0.2018 Tw T*
[(lated ferritin was low)64.8 (, less than 20%, in all cases tested)]TJ
0.0343 Tw T*
[(during the acute phase of the disease \(mean 8.4 \261)-269.2 (3%, 95%)]TJ
0.0462 Tw T*
(CI 0.08\). During remission, while the ferritin level normal-)Tj
-0.002 Tw T*
(izes, the percentage of glycosylated ferritin remained low in)Tj
0.11169 Tw T*
[(2/3 cases. )17.7 (This has also been reported in )54.8 (ASD remission)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 288.25 524.4616 Tm
(9)Tj
10 0 0 10 291.4999 521.1616 Tm
(.)Tj
-0.00011 Tc -0.02451 Tw -23.75 -1.2 Td
[(This may suggest that in some patients with )54.9 (ASD or NHML,)]TJ
0.1059 Tw T*
(although they are considered to be in clinical remission, a)Tj
0.2005 Tw T*
(low grade of macrophage activation persists. Contrasting)Tj
0.1647 Tw T*
[(with data reported in )54.8 (ASD, we did not find a correlation)]TJ
0.14729 Tw T*
(between C-reactive protein level and ferritin levels in the)Tj
0.02499 Tw T*
(patients described.)Tj
/T1_0 1 Tf
0 Tw 0 -2.4 TD
(DISCUSSION)Tj
/T1_1 1 Tf
0.0377 Tw 0 -1.2 TD
[(W)79.9 (e conclude the combination of high ferritin level and low)]TJ
0.1797 Tw T*
[(glycosylation percentage is not specific to )54.8 (ASD, but is a)]TJ
0.1468 Tw T*
(marker of excessive macrophage activation. Inflammation)Tj
0.0843 Tw T*
(and fever may induce a high ferritin level by the action of)Tj
0.2173 Tw T*
(interleukin 1\247, which increases ferritin synthesis)Tj
0 Tc 0 Tw 6.5 0 0 6.5 258.6745 368.4616 Tm
(10)Tj
-0.00011 Tc 0.21719 Tw 10 0 0 10 265.1745 365.1616 Tm
(. Liver)Tj
0.371 Tw 5.2826 34.8 Td
(cell damage and ferritin release by macrophages after)Tj
0.1879 Tw T*
(erythrophagocytosis may be other factors of high ferritin)Tj
0 Tw T*
(concentrations.)Tj
/T1_0 1 Tf
0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 325 655.1616 Tm
[(1.)-875.1 (Gonzalez-Hernandez )17.7 (T)74 (, Martin-Mola E, Fernandez-Zamorano )54.8 (A,)]TJ
1.675 -1.25 Td
[(Balsa-Criado )54.8 (A, de Miguel-Mendieta E. Serum ferritin can be)]TJ
0 -1.25 TD
[(useful for diagnosis in adult onset Still\325)54.8 (s disease. J Rheumatol)]TJ
0 Tc 0 Tw T*
(1989;16:412-3.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Esumi N, Ikushima S, )17.7 (T)69.9 (odo S, Imashuku S. Hyperferritinemia in)]TJ
1.675 -1.25 Td
(malignant histiocytosis and virus-associated hemophagocytic)Tj
T*
(syndrome. N Engl J Med 1987;316:346-7.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (Cof)17.7 (fernils M, Soupart )54.8 (A, Pradier O, Feremans )17.7 (W)91.8 (, N\217ve P)110.7 (, Decaux)]TJ
1.675 -1.25 Td
[(G. Hyperferritinemia in adult onset Still\325)54.8 (s disease and the)]TJ
T*
(hemophagocytic syndrome. J Rheumatol 1992;19:1425-7.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Kumakura S, Ishikura H, Munemasa S, )54.8 (Adachi )17.7 (T)74 (, Murakawa )36.8 (Y)128.9 (,)]TJ
1.675 -1.25 Td
[(Kobayashi S. )54.8 (Adult onset Still\325)54.8 (s disease associated)]TJ
T*
(hemophagocytosis. J Rheumatol 1997;24:1645-8.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Fautrel B, Le Moel G, Saint-Marcoux B, et al. Diagnostic value of)]TJ
1.675 -1.25 Td
[(ferritin and glycosylated ferritin in adult onset Still\325)54.8 (s disease. )]TJ
T*
(J Rheumatol 2001;28:322-9.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (V)110.8 (an Reeth C, Le Moel G, Lasne )36.8 (Y)128.9 (, et al. Serum ferritin and)]TJ
1.675 -1.25 Td
[(isoferritins are tools for diagnosis of active adult Still\325)54.8 (s disease. )]TJ
T*
(J Rheumatol 1994;21:890-5.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (W)79.9 (orwood M, Cragg S, )17.7 (W)79.9 (agstaf)17.7 (f M, Jacobs )54.8 (A. Binding of human)]TJ
1.675 -1.25 Td
[(serum ferritin to concanavalin )54.8 (A. Clin Sci 1979;56:83-7.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Lambotte O, Costedoat-Chalumeau N, )54.8 (Amoura Z, Piette JC,)]TJ
1.675 -1.25 Td
[(Cacoub P)110.8 (. Drug-induced hemophagocytosis. )54.8 (Am J Med)]TJ
0 Tc 0 Tw T*
[(2002;1)36.9 (12:592-3.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (V)59.8 (ignes S, Le Moel G, Fautrel B, )17.7 (W)79.9 (echsler B, Godeau P)110.7 (, Piette JC.)]TJ
1.675 -1.25 Td
(Percentage of glycosylated serum ferritin remains low throughout)Tj
T*
[(the course of adult onset Still\325)54.8 (s disease. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2000;59:347-50.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (T)69.9 (orti FM, )17.7 (T)69.9 (orti SV)128.8 (. Regulation of ferritin genes and protein. Blood)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2002;99:3505-17.)Tj
ET
0 0 0 0 scn
420 777 137 -27 re
f*
BT
0 0 0 1 scn
/T1_2 1 Tf
-0.00011 Tc 20.37 0 0 21 460.9631 760.6089 Tm
(\002\003\003\002\004\005\006\002\004\002)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/T1_3 1 Tf
0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:5)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1028)Tj
ET
0 0 0 0 scn
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 scn
/GS1 gs
/T1_3 1 Tf
-0.00011 Tc 0.0251 Tw 8 0 0 8 55 338.5293 Tm
[(T)91.8 (able 1.)]TJ
/T1_1 1 Tf
3.4858 0 Td
(Characteristics of patients with hemophagocytosis admitted over 3 years.\
)Tj
7.2 0 0 8 55 318.5293 Tm
[(Case)-501 (Sex/)-1278.4 (Diagnosis)-2103.3 (T)35 (ime of)-1631.3 (Ferritin)-972.8 (GF)79.8 (, %)-1291.5 (ESR, )-807.7 (CPR, )-919.4 (Fibrinogen,)-807 (Leukocytes,)-1140.2 (Hb,)-1875.9 (Platelets)-1862.3 (LDH)-3051.5 (ASA)110.7 (T)74 (,)-2713.5 (ALA)110.8 (T)74 (,)-1551.4 (Bilirubin)]TJ
-0.0002 Tc 0 Tw 2.5005 -1.25 Td
(Age)Tj
8.7772 0 Td
[(Sampling)-1667.6 (Level)]TJ
12.83243 0 Td
[(mm/h)-1111.1 (mg/l)-3138.9 (g/l)-3948.7 (/mm)]TJ
0 Tc 4.68 0 0 5.2 338.4306 311.1693 Tm
(3)Tj
-0.0002 Tc 7.2 0 0 8 358.3996 308.5293 Tm
[(g/dl)-2448.7 (/mm)]TJ
0 Tc 4.68 0 0 5.2 400.4306 311.1693 Tm
(3)Tj
-0.0002 Tc 7.2 0 0 8 416.6059 308.5293 Tm
[(\(normal)-2251.8 (\(normal)-2251.8 (\(normal)-1557.4 (\(normal)]TJ
-0.00011 Tc 0.02499 Tw -33.8889 -1.25 Td
[(\(normal)-30028 (< 440 UI/l\))-1109.7 (< 34 UI/l\))-1359.7 (< 34 UI/l\))-1774.3 (< 17 )]TJ
-0.7066 -1.25 Td
[(< 300 \265)-76 (g/l\))]TJ
-0.0002 Tc 0 Tw 50.2236 0 Td
[(\265)-76.1 (mol/l\))]TJ
0 Tc 0.02499 Tw -65.8511 -2.5 Td
[(1)-1751.4 (M 40)-1612.9 (NHML)-3028.9 (Acute)-2528.5 (8283)-2500 (7)-2879.5 (1)36.9 (1)-2212.9 (67)-3458.3 (1.2)-3930.5 (1580)-2680.6 (5.8)-2305.6 (55,000)-2208.3 (2694)-3666.7 (154)-3916.7 (408)-3222.2 (177)]TJ
-0.00011 Tc 0 Tw 11.7508 -1.25 Td
(disease)Tj
0 Tc 0.0249 Tw -11.7508 -1.25 Td
[(2)-1917.9 (F 52)-697.7 (Serious drug)-1947.2 (Acute )-2253.6 (2470)-2028.1 (ND)-2139.2 (106)-1944.4 (62)-3458.3 (5.1)-3930.5 (1800)-2680.6 (7.3)-2305.6 (17,000)-2226.8 (1)36.9 (150)-3685.1 (345)-3916.7 (331)-3722.2 (4)]TJ
-0.00011 Tc 0 Tw 4.3063 -1.25 Td
[(hypersensitivity)-1057.2 (disease)]TJ
0 Tc 0.0249 Tw 1.222 -1.25 Td
[(syndrome)-2835.4 (At 6)-3084.8 (106)-2500 (30)-2611.1 (47)-2444.4 (4)-3708.3 (4.2)-3930.5 (5520)-2449 (1)36.9 (1.1)-1824 (180,000)-2597.4 (N)-4694.7 (N)-4694.7 (N)-4000.2 (N)]TJ
-0.0002 Tc 0 Tw 7.0272 -1.25 Td
(mo)Tj
0 Tc 0.02499 Tw -12.5555 -1.25 Td
[(3)-1917.9 (F 35)-1779.4 (NHML)-3028.9 (Acute)-2778.5 (746)-2750 (7)-2611.1 (125)-1944.4 (16)-3458.3 (1.1)-3930.5 (1290)-2680.6 (7.7)-2305.6 (22,000)-2208.3 (1405)-3916.7 (95)-4416.7 (44)-3722.2 (10)]TJ
-0.00011 Tc 0 Tw 11.7508 -1.25 Td
(disease)Tj
0 Tc 0.02499 Tw -11.7508 -1.25 Td
[(4)-1917.9 (F 23)-1779.4 (NHML)-3028.9 (Acute )-2271.9 (1)36.9 (172)-2286.9 (1)36.9 (1)-2629.5 (36)-2194.4 (88)-3458.3 (5.3)-3930.5 (4400)-2680.6 (9.2)-2055.6 (348,000)-1958.3 (1024)-3916.7 (66)-4416.7 (51)-3722.2 (15)]TJ
-0.00011 Tc 0 Tw 11.7508 -1.25 Td
(disease)Tj
0 Tc -0.6675 -1.25 Td
[(Remission)-1861.1 (120)-2750 (5)-3111.1 (4)-2694.5 (6)-3708.3 (3.8)-3930.5 (4500)-2430.6 (10.2)-1805.6 (442,000)-2208.3 (337)-4166.7 (27)-4416.7 (22)-3972.2 (9)]TJ
0.02499 Tw -11.0834 -1.25 Td
[(5)-1751.4 (M 30)-1612.9 (NHML)-3028.9 (Acute)-2153.5 (18,079)-1705.5 (< 5)-2691.6 (1)-2444.4 (13)-3458.3 (1.2)-3930.5 (1490)-2680.6 (9.3)-2305.6 (82,000)-2208.3 (5043)-3685.1 (1)36.9 (19)-3953.5 (1)36.9 (16)-3740.7 (8)]TJ
-0.00011 Tc 0 Tw 11.7508 -1.25 Td
(disease)Tj
0 Tc 0.02499 Tw -11.7508 -1.25 Td
[(6)-1917.9 (F 60)-1779.4 (NHML)-2111.6 (Remission)-1861.1 (145)-2500 (42)-2611.1 (36)-2194.4 (14)-3458.3 (3.7)-3930.5 (2330)-2430.6 (12.3)-1805.6 (212,000)-2597.4 (N)-4694.7 (N)-4694.7 (N)-4000.2 (N)]TJ
T*
[(7)-1917.9 (F 45)-697.7 (Serious drug)-1947.2 (Acute)-2153.5 (14,520)-1875 (12)-2611.1 (51)-2194.4 (41)-3458.3 (1.6)-3930.5 (1200)-2680.6 (8.1)-2055.6 (100,000)-1958.3 (3775)-3666.7 (181)-3916.7 (133)-3722.2 (6)]TJ
-0.00011 Tc 0 Tw 4.3063 -1.25 Td
[(hypersensitivity)-1057.2 (disease)]TJ
1.222 -1.25 Td
(syndrome)Tj
0.2085 Tw -5.5283 -2.5 Td
[(GF: glycosylated ferritin, N: 50\32080%; NHML: non-Hodgkin\325)54.9 (s malignant lymphoma; ESR: erythrocyte sedimentation rate; CRP: C-react)-1.9 (ive protein; Hb: hemoglobin; )]TJ
0.02499 Tw T*
(LDH: lactate dehydrogenase; ND: not done.)Tj
ET
54 332 m
557 332 l
54 282 m
558 282 l
54 102 m
558 102 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
38 0 obj
<>
endobj
33 0 obj
<>
endobj
24 0 obj
<>
endobj
22 0 obj
<>
endobj
63 0 obj
<>
endobj
73 0 obj
<>
endobj
23 0 obj
<>
endobj
58 0 obj
<>stream
HUiPSY~/浃SpWmF$BHHKH@6 wťۥTƍ۞ikVx:G:u}uScnq呫""çEҥ+i-YƎ v"u<.3͋8Ɗ|֝؎CrCc`ȧe7|q}%Lu,%UL{fO?yC̢dyR+t"c<;S&KfQZ`
iv+cF`evb4=1{;#D2JuYIH!fd.B%eRԾ|w°̇D876Ű1-;'[$F`$G,3avpfrT~b)wts߹{ẠcsgQF]
:<:dt諼h1<~mVЗ?736E/h|'tB!m Wv3}h{ϴ*KoեVI6>e"7=_RIg5߽"n!o) *`Q*a0q-PrJ>Wdw{luc ,h ̃N2˩\WuSPJ}MJgVN3/?k%g`ɓ]vsmjAֽbXi%兦1bFzmHZݓ+ջļG84D`Fj6"VwrPVM鏈JCZM\}vͦKu_g"+: ?v<ùD-m=a4Eʹ`F~?aks4EYJ-ٍ,,(q/y&Nthlӗc{>*N*4jU
aV
RI`*Z/rQ,#WG%wLqx (mEQHb'Ma|$&4BPDY&KO };_tZlϊc44evR<0
8c'X3q'F&)4fkDXcgJۊ\Bܝ)+2M!+bXBa|Si{g!N'FJ2\Y"t _]'9v9E
`5*6wTTU4Z
k$a"(('ʯmwSևlY|%_Dzx++veEkꥶyBGEEUSgUۣ
fKuS^[(,vj5-xx)m
l4sCdh|X~Pw+zrjCI)u`7c-Mٸ2Z(lqgM
"4NZ
OhӰPxx+?`B~HpU?Qh%yf+nR#tp
C.O$/S954Iyk:ArO;&TD9Dňqv [=We@D#N^"a&CԱ{:D.'-[Xp"1=riry "Q6R52,o:(s3fAIImv&jgӨzf G4?
v#oLNY2iltI}2>VkBR߫ycӡb9l1\a,P<-']t;\u07EOFUwi(s[(V;)e$!0yBs+\}f5\u,9E芜hYM({
$fSC33#:
rb{~ eogKUC'g21u4>wcw$X?V&x)U8e, M
`6<ɗs:OhJLHho9ނeq3cBc84<'9Oo p6E{}.&cxr7lPz٤w܂A5#?%K#0--=>F
]Hx6qRmot~ӉZX;"11ZX@Z.6D鏥L<\_| ֓ &OUt7gނ;@_x~Kt Ģ9,!3>s.#fɴ}faӅvh|kXr
N!|c"WnjN[(9Š$WbCCɞ~Mf?ă9X7&s{!qt%g˜=